Amendments to the Claims/Listing of Claims

Please amend claims 1, 9, 17, 18, 25, 29 and 30, and cancel claims 2 and 19 as follows. This listing of claims will replace all prior versions, and listings of claims in the application:

1. (Currently amended) A method for treating hyperplasia in a subject in need thereof, said method comprising administering to said subject an effective amount of a composition comprising **an amorphous** drug **in nanoparticle form,** coated with a protein, **wherein said drug is selected from the group consisting of an antineoplastic, an antiproliferative, an angiogenesis inhibitor, and mixtures of any two or more thereof**.

2. (Cancelled).

3. (Original) A method according to claim 1 wherein said hyperplasia occurs in blood vessel neointima.

4. (Original) A method according to claim 1 wherein said effective amount falls in the range of about 0.01 mg/kg up to about 15 mg/kg for a human subject.

5. (Original) A method according to claim 4 wherein said administration of said composition is repeated over a dosing cycle between 1 day and 6 months.

6. (Original) A method according to claim 1 wherein said composition is administered systemically.

7. (Original) A method according to claim 6 wherein administration is accomplished intra-arterially, intravenously, by inhalation, or orally.

8. (Original) A method according to claim 1 wherein said composition is administered before, during or after the occurrence of said hyperplasia.

9. (Currently amended) A method for reducing neointimal hyperplasia associated with vascular interventional procedure(s) in a subject in need thereof, said method comprising administering to said subject an effective amount of a composition comprising at least one **amorphous** drug **in nanoparticle form**, coated with a protein, **wherein said drug is selected from the group consisting of an antineoplastic, an antiproliferative, an angiogenesis inhibitor, and mixtures of any two or more thereof**.

10. (Original) A method according to claim 9 wherein said procedure comprises angioplasty, stenting or atherectomy.

11. (Original) A method according to claim 9 wherein said composition is administered before, during or after the vascular interventional procedure.

12. (Original) A method according to claim 9 wherein said composition is administered at the time of the vascular interventional procedure.

13. (Original) A method according to claim 9 wherein said effective amount falls in the range of about 0.01 mg/kg up to about 15 mg/kg for a human subject.

14. (Original) A method according to claim 13 wherein said administration of said composition is repeated over a dosing cycle between 1 day and 6 months.

15. (Original) A method according to claim 9 wherein said composition is administered systemically.

16. (Original) A method according to claim 9 wherein said composition is administered by deployment of a stent containing said at least one drug coated thereon.

17. (Currently amended) A method to reduce proliferation and cell migration in a subject undergoing a vascular interventional procedure, said method comprising systemically administering **to said subject before, during or after said procedure,** a formulation comprising **(i) an amorphous** drug **in nanoparticle form, wherein said drug** ~~**that**~~ inhibits proliferation and cell migration, and **(ii)** a biocompatible protein ~~**to said subject before, during or after said procedure**~~, wherein said drug is coated with said protein**, and wherein said drug is selected from the group consisting of an antineoplastic, an antiproliferative, an angiogenesis inhibitor, and mixtures of any two or more thereof**.

18. (Currently amended). A composition for treatment of hyperplasia, said composition comprising **(i)** at least one **amorphous** drug **in nanoparticle form,** and **(ii)** protein**, wherein said drug is selected from the group consisting of an antineoplastic, an antiproliferative, an angiogenesis inhibitor, and mixtures of any two or more thereof**.

19. (Cancelled).

20. (Original) A composition according to claim 18 wherein said hyperplasia occurs in blood vessel neointima.

21. (Original) A composition according to claim 18 wherein said drug is a taxane or analog or homolog thereof, an epothilone or analog or homolog thereof, or a rapamycin or analog or homolog thereof.

22. (Original) A composition according to claim 21 wherein said taxane is paclitaxel.

23. (Original) A composition according to claim 18 wherein said composition is suitable for systemic administration.

24. (Original) A composition according to claim 23 wherein administration is accomplished intra-arterially, intravenously, by inhalation, or orally.

25. (Currently amended) A composition for reducing neointimal hyperplasia associated with vascular interventional procedure(s), said composition comprising at least one **amorphous** drug **in nanoparticle form,** coated with ~~and~~ a protein**, wherein said drug is selected from the group consisting of an antineoplastic, an antiproliferative, an angiogenesis inhibitor, and mixtures of any two or more thereof**.

26. (Original) A composition according to claim 25 wherein said procedure is angioplasty, stenting or atherectomy.

27. (Original) A composition according to claim 25 wherein said composition is suitable for systemic administration.

28. (Original) A composition according to claim 27 wherein administration is accomplished intra-arterially, intravenously, by inhalation, or orally.

29. (Currently amended) A method to reduce the toxicity of a drug that inhibits proliferation and migration of cells, said method comprising combining said drug**, in amorphous form and in the form of nanoparticles,** with a biocompatible protein, wherein said drug is coated with said protein**, wherein said drug is selected from the group consisting of an antineoplastic, an antiproliferative, an angiogenesis inhibitor, and mixtures of any two or more thereof**.

30. (Currently amended) A pharmaceutical formulation with reduced toxicity, said formulation comprising a**n amorphous** drug **in nanoparticle form, wherein said drug** ~~that~~ inhibits proliferation and cell migration, **wherein said drug is** coated with a biocompatible protein**, and wherein said drug is selected from the group consisting of an antineoplastic, an antiproliferative, an angiogenesis inhibitor, and mixtures of any two or more thereof**.